Enteric Softgel Capsules MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy End UserBy Distribution ChannelBy Manufacturing Technology

Enteric softgel capsules are a soft-shell capsule format coated or formulated so that the fill dissolves only after passing through the stomach, protecting acid-sensitive active ingredients or shielding the stomach lining from irritating compounds. They are used to deliver pharmaceutical actives such as antacids, antibiotics and cardiovascular drugs as well as nutraceutical ingredients like probiotics, enzymes and certain vitamins. Buyers are pharmaceutical manufacturers, dietary-supplement and nutraceutical brands, and the contract encapsulation and fill-finish operations that produce softgels on their behalf.

The global enteric softgel capsules market stood at USD 2.75 billion in 2025. A forecast-period rate of 6.98% takes it to USD 4.99 billion by 2034, and the study reports every year in between, passing USD 2.02 billion in 2020, USD 2.6 billion in 2024, USD 2.91 billion in 2026 and USD 3.79 billion in 2030.

The type mix shifts over the period. Gelatin Type is the largest line in 2025 at USD 1.87 billion, a 68% share, moving to USD 2.89 billion and 57.9% by 2034. Vegetable Type grows fastest at 10.28%, taking its share from 32% to 42.1%, while Gelatin Type grows slowest at 5.04%. The lines gaining share are Vegetable Type. Gelatin Type lose share without losing revenue.

Cut by application, the largest line is Antacid and Antiflatulent Preparations: 34.2% of 2025 revenue, worth USD 0.94 billion, and 30.1% at USD 1.5 billion by 2034. Vitamins and Dietary Supplements grows faster at 9.55% against 5.33%, moving from 24% of revenue to 30.1% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.

Geographically, 34.2% of 2025 revenue sits in Asia Pacific (USD 0.94 billion rising to USD 1.9 billion) ahead of North America at 30.2% and USD 0.83 billion. Middle East and Africa is smallest, at 4.7%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is a triangulation of published figures and category proxies rather than a directly sourced total. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, two type lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 2.75 billion in 2025 to USD 4.99 billion in 2034, a compound annual rate of 6.98%, having reached USD 2.6 billion in 2024 from USD 2.02 billion in 2020.
• Gelatin Type is the largest type line at USD 1.87 billion in 2025, a 68% share, reaching USD 2.89 billion and 57.9% of revenue by 2034.
• At 10.28%, Vegetable Type grows faster than any other type line, moving from USD 0.88 billion and 32% of revenue in 2025 to USD 2.1 billion and 42.1% in 2034.
• The bull case puts 2034 revenue at USD 5.66 billion and the bear case at USD 4.44 billion, either side of the USD 4.99 billion base case, each with its own stated assumption in the full report.
• 34.2% of 2025 revenue is generated in Asia Pacific, worth USD 0.94 billion and rising to USD 1.9 billion by 2034; Middle East and Africa is smallest at 4.7%.
• 41.5% of Asia Pacific's base-year revenue comes from China alone: USD 0.39 billion in 2025, rising to USD 0.76 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 6.98% compounding underneath both.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Vegetable Type outpaces Gelatin Type. Vegetable Type grows at 10.28% across 2026-2034 against 5.04% for Gelatin Type, the widest spread on the type axis. Vegetable Type takes its share of revenue from 32% to 42.1% while Gelatin Type gives up ground, from 68% to 57.9%. Revenue rises on both sides; USD 0.88 billion to USD 2.1 billion and USD 1.87 billion to USD 2.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 34.2% of revenue in 2025 to 38.1% in 2034, worth USD 0.94 billion rising to USD 1.9 billion; Latin America moves from 6.9% of revenue in 2025 to 8% in 2034, worth USD 0.19 billion rising to USD 0.4 billion; Middle East and Africa moves from 4.7% of revenue in 2025 to 4.8% in 2034, worth USD 0.13 billion rising to USD 0.24 billion. The remaining regions grow in absolute terms while giving up share: North America at 30.2% moving to 27.1%, Europe at 24% moving to 22%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

A continuation, not an inflection. Reading the series: USD 2.02 billion in 2020, USD 2.6 billion in 2024, USD 2.75 billion in 2025, USD 2.91 billion in 2026, USD 3.79 billion in 2030 and USD 4.99 billion in 2034. Against 6.37% through the historical period, the 6.98% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.

Vegetable Type carries the market's growth rate

Separate the 6.98% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.

The bear case and what drives it

Where the forecast could be beaten

Revenue is concentrated in Gelatin Type

North America holds 30.2% of the global enteric softgel capsules market in 2025, worth USD 0.83 billion on the way to USD 1.35 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 27.1%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Gelatin Type the largest line at 68% of 2025 revenue and Vegetable Type the fastest-growing at 10.28%. North America is reported axis by axis and country by country in the full study.

81.9% of North America's base-year revenue comes from the United States; USD 0.68 billion, rising to USD 1.08 billion by 2034. Because it is 81.9% of the region in the base year, North America's totals move with this one country rather than with a spread of them. The region itself runs USD 0.83 billion to USD 1.35 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Gelatin Type at 68% of 2025 revenue, easing to 57.9% by 2034, and the fastest is Vegetable Type at 10.28%, from 32% to 42.1%. Its 81.9% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.

In the United States, enteric-coated softgel capsules fall under the oversight of the Food and Drug Administration, with the applicable pathway depending on whether the product is marketed as a conventional pharmaceutical or as a dietary supplement. Pharmaceutical-grade softgels require approval through the New Drug Application or Abbreviated New Drug Application process, demonstrating safety, efficacy, and manufacturing quality under current Good Manufacturing Practice rules. Supplement-grade products instead fall under the Dietary Supplement Health and Education Act, which does not require premarket approval but obligates manufacturers to follow dietary supplement current Good Manufacturing Practice regulations, substantiate label claims, and avoid disease-treatment claims reserved for drugs. Labelling must accurately disclose ingredients, dosage form, and supplement facts.

The suppliers tracked in this study (Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.) compete in the United States across the type lines above. Gelatin Type, at 68% of 2025 revenue, is where the volume sits, and Vegetable Type, growing at 10.28%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 18.1% of regional revenue and 5.5% of the global total, worth USD 0.15 billion in 2025 and USD 0.27 billion by 2034.

24% of the global enteric softgel capsules market sits in Europe in 2025, worth USD 0.66 billion rising to USD 1.1 billion in 2034. Among the five regions it ranks third by revenue in both years.

Its share moves to 22% by 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. Europe is reported axis by axis and country by country in the full study.

36.4% of Europe's base-year revenue comes from Germany; USD 0.24 billion, rising to USD 0.39 billion by 2034. It accounts for 36.4% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.66 billion in 2025 and USD 1.1 billion in 2034, it is the country the full report breaks out in detail.

Germany buys along the same lines as the market globally; Gelatin Type first at 68% of 2025 revenue and 57.9% in 2034, Vegetable Type fastest at 10.28% on a share moving from 32% to 42.1%. Since 36.4% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Germany by type separately.

In Germany, enteric softgel capsules are regulated within the broader European Union medicinal products and food supplement frameworks, with the German Federal Institute for Drugs and Medical Devices, BfArM, overseeing products classified as medicinal. A softgel marketed as a medicinal product requires authorization either nationally or through the European Medicines Agency's centralized procedure, with conformity to Good Manufacturing Practice and the EU Pharmaceutical Directive's quality and labelling standards. Where the softgel is classified instead as a food supplement, it falls under the EU Food Supplements Directive, requiring notification to national authorities, compliance with maximum permitted ingredient levels, and labelling that avoids medicinal claims while disclosing composition, allergens, and recommended use clearly.

Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd. are the suppliers covered in Germany. The commercially relevant division is 68% of 2025 revenue in Gelatin Type, where the volume is, against 10.28% growth in Vegetable Type, where share moves.

France is sized at USD 0.16 billion in 2025, rising to USD 0.25 billion by 2034; 5.8% of global revenue and 24.2% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 34.2% of global revenue puts 2025 at USD 0.94 billion rising to USD 1.9 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 38.1% over the forecast period, so the region grows faster than the market's 6.98% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. Per-axis and per-country detail for Asia Pacific sits in the full report.

China is the largest market within Asia Pacific, generating USD 0.39 billion in 2025 and projected to reach USD 0.76 billion by 2034. 41.5% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.94 billion in 2025 and USD 1.9 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Gelatin Type at 68% of 2025 revenue, easing to 57.9% by 2034, and the fastest is Vegetable Type at 10.28%, from 32% to 42.1%. With 41.5% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports China by type separately.

In China, enteric softgel capsules are regulated according to their classification as either a pharmaceutical or a health food product. Pharmaceutical-grade softgels fall under the National Medical Products Administration, which requires drug registration, clinical evidence, and conformity with Good Manufacturing Practice before market entry. Health food, or so-called Blue Hat, softgels are instead regulated by the State Administration for Market Regulation, requiring registration or filing depending on ingredient novelty, along with adherence to national food safety standards and labelling rules that prohibit therapeutic claims. Both routes demand accurate disclosure of ingredients, dosage instructions, and manufacturer information, alongside facility licensing appropriate to the product's classification.

Competition in China runs between the suppliers this study tracks: Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.. Gelatin Type, at 68% of 2025 revenue, is where the volume sits, and Vegetable Type, growing at 10.28%, is where position changes hands over the forecast period.

Within Asia Pacific, India accounts for 22.3% of regional revenue and 7.6% of the global total, worth USD 0.21 billion in 2025 and USD 0.46 billion by 2034.

Within Asia Pacific, Japan accounts for 16% of regional revenue and 5.5% of the global total, worth USD 0.15 billion in 2025 and USD 0.29 billion by 2034.

USD 0.19 billion of 2025 revenue is generated in Latin America, 6.9% of the global enteric softgel capsules market and reaches USD 0.4 billion by 2034. Among the five regions it ranks fourth by revenue in both years.

Its share rises to 8% over the forecast period, so the region grows faster than the market's 6.98% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. The full report breaks Latin America out along every axis and by country.

52.6% of Latin America's base-year revenue comes from Brazil; USD 0.1 billion, rising to USD 0.19 billion by 2034. At 52.6% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Against regional totals of USD 0.19 billion in 2025 and USD 0.4 billion in 2034, it is the country the full report breaks out in detail.

The type pattern in Brazil is the global one: 68% of 2025 revenue in Gelatin Type, 57.9% by 2034, against 10.28% growth in Vegetable Type taking it from 32% to 42.1%. Since 52.6% of Latin America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by type for Brazil is reported separately in the full report.

In Brazil, enteric softgel capsules are regulated by the National Health Surveillance Agency, ANVISA, which classifies the product according to its intended use as either a medicine or a food supplement. Medicinal softgels require registration demonstrating safety, quality, and efficacy, along with adherence to Good Manufacturing Practice standards enforced through ANVISA inspection. Softgels marketed as food supplements fall under ANVISA's specific food supplement resolution, which sets requirements for permitted ingredients, maximum intake recommendations, and labelling that must avoid disease-related claims while clearly stating composition and directions for use. Import and domestic manufacture alike require sanitary licensing and ongoing compliance with ANVISA's post-market surveillance obligations.

The suppliers tracked in this study (Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.) compete in Brazil across the type lines above. Volume sits in Gelatin Type at 68% of 2025 revenue; movement sits in Vegetable Type at 10.28% growth.

Within Latin America, Mexico accounts for 31.6% of regional revenue and 2.2% of the global total, worth USD 0.06 billion in 2025 and USD 0.12 billion by 2034.

USD 0.13 billion of 2025 revenue is generated in Middle East and Africa, 4.7% of the global enteric softgel capsules market and reaches USD 0.24 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

By 2034 the share has moved up to 4.8%, on growth above the market's own 6.98%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Gelatin Type leads here as it does globally, at 68% of 2025 revenue, and Vegetable Type again grows fastest at 10.28%. Middle East and Africa is reported axis by axis and country by country in the full study.

USD 0.05 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.08 billion by 2034. At 38.5% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 0.13 billion in 2025 and USD 0.24 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Saudi Arabia buys along the same lines as the market globally; Gelatin Type first at 68% of 2025 revenue and 57.9% in 2034, Vegetable Type fastest at 10.28% on a share moving from 32% to 42.1%. Since 38.5% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Saudi Arabia by type separately.

In Saudi Arabia, enteric softgel capsules fall under the jurisdiction of the Saudi Food and Drug Authority, SFDA, which determines classification as either a pharmaceutical or a food supplement depending on ingredient composition and intended claims. Pharmaceutical-grade softgels require registration demonstrating safety and quality in line with SFDA's drug regulations and Good Manufacturing Practice conformity. Food supplement softgels instead follow the SFDA's food supplement regulation, requiring product notification or registration, ingredient limits aligned with Gulf Cooperation Council standards, and labelling in Arabic disclosing composition, usage directions, and cautionary statements. Importers and manufacturers must hold valid SFDA licensing and maintain conformity throughout the product's distribution.

Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd. are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Gelatin Type at 68% of 2025 revenue, and taking Vegetable Type while it grows at 10.28%.

Within Middle East and Africa, South Africa accounts for 23.1% of regional revenue and 1.1% of the global total, worth USD 0.03 billion in 2025 and USD 0.06 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, end user, distribution channel, manufacturing technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.